CLONIDINE TO PREVENT IMPLANTABLE CARDIOVERTER DEFIBRILLATOR FIRING

可乐定可防止植入式心脏复律除颤器起火

• 批准号: 7604906
• 负责人: James B Martins
• 金额: $ 0.04万
• 依托单位: UNIVERSITY OF IOWA
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604906
• 关键词: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Cardiac; Clonidine; Computer Retrieval of Information on Scientific Projects Database; Data; Devices; Drug Prescriptions; End Point; Fire - disasters; Funding; Grant; Heart Arrest; Heart Diseases; Implantable Defibrillators; Informed Consent; Institution; Invasive; Metoprolol; Patients; Pharmaceutical Preparations; Purpose; Randomized; Research; Research Personnel; Resources; Shock; Source; Testing; Time; United States National Institutes of Health; Ventricular Tachycardia; base; blind; day; improved; outcome forecast; prevent; programs

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Cardiac arrest or sustained ventricular tachycardia (VT) in patients with heart disease is best treated with an implantable cardioverter defibrillator (ICD). However, the ICD alone is not appropriate therapy for patients with frequent VT episodes. In fact, frequent shocks for VT may predict a poorer prognosis. Antiarrhythmic drugs are co-administered with ICDs in up to 50% of patients to prevent VT episodes, but antiarrhythmic drugs may have harmful effects. Thus, improved drugs to prevent VT without interfering with ICD function are needed. Recent data suggest that clonidine may be a new therapy to prevent ICD shocks. It may act centrally on sympathetic outflow and peripherally and selectively on cardiac Purkinje to suppress and control VT occurring in patients. The purpose of this study is to test the hypothesis that clonidine reduces frequent VT better than beta blocker in patients with ICDs. After informed consent, patients will be randomized in a single blind fashion to either clonidine or metoprolol given three times per day. Other prescribed drugs may be adjusted to promote toleration of the study drug. ICD interrogrations of episodes of VT will be the primary endpoint. Device based non-invasive programmed stimulation (NIPS) testing in a subset of these patients will allow mechanistic understanding of the clonidine effect.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 心脏病患者的心脏骤停或持续性室性心动过速（VT）最好用植入式心律转复除颤器（ICD）治疗。 然而，单独使用ICD并不适用于频繁VT发作的患者。 事实上，VT的频繁电击可能预示预后较差。 高达50%的患者将抗心律失常药物与ICD联合给药，以预防VT发作，但抗心律失常药物可能具有有害作用。 因此，需要改进的药物来预防VT而不干扰ICD功能。 最近的数据表明，可乐定可能是一种新的治疗，以防止ICD休克。 它可中枢作用于交感神经流出，外周和选择性地作用于心脏浦肯野，以抑制和控制患者发生的VT。 本研究的目的是检验可乐定比β受体阻滞剂更能降低ICD患者频发VT的假设。 在知情同意后，患者将以单盲方式随机分配至可乐定或美托洛尔组，每天给药三次。 可调整其他处方药物，以促进研究药物的耐受性。 ICD询问VT发作将是主要终点。 在这些患者的一个子集中进行基于器械的无创程控刺激（NIPS）测试将允许对可乐定效应的机制性理解。